These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22177145)

  • 1. Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers.
    Shariat SF; Chromecki TF; Cha EK; Karakiewicz PI; Sun M; Fradet Y; Isbarn H; Scherr DS; Bastian PJ; Pummer K; Fajkovic H; Sagalowsky AI; Ashfaq R; Doblinger M; Cote RJ; Lotan Y
    J Urol; 2012 Feb; 187(2):457-62. PubMed ID: 22177145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy.
    Lotan Y; Bagrodia A; Passoni N; Rachakonda V; Kapur P; Arriaga Y; Bolenz C; Margulis V; Raj GV; Sagalowsky AI; Shariat SF
    Eur Urol; 2013 Sep; 64(3):465-71. PubMed ID: 23571005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
    Shariat SF; Tokunaga H; Zhou J; Kim J; Ayala GE; Benedict WF; Lerner SP
    J Clin Oncol; 2004 Mar; 22(6):1014-24. PubMed ID: 14981102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients.
    Tilki D; Reich O; Svatek RS; Karakiewicz PI; Kassouf W; Novara G; Ficarra V; Chade DC; Fritsche HM; Gerwens N; Izawa JI; Lerner SP; Schoenberg M; Stief CG; Skinner E; Lotan Y; Sagalowsky AI; Shariat SF
    J Urol; 2010 May; 183(5):1757-63. PubMed ID: 20299059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy.
    Shariat SF; Karakiewicz PI; Ashfaq R; Lerner SP; Palapattu GS; Cote RJ; Sagalowsky AI; Lotan Y
    Cancer; 2008 Jan; 112(2):315-25. PubMed ID: 18008359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 predictive value for pT1-2 N0 disease at radical cystectomy.
    Shariat SF; Lotan Y; Karakiewicz PI; Ashfaq R; Isbarn H; Fradet Y; Bastian PJ; Nielsen ME; Capitanio U; Jeldres C; Montorsi F; Müller SC; Karam JA; Heukamp LC; Netto G; Lerner SP; Sagalowsky AI; Cote RJ
    J Urol; 2009 Sep; 182(3):907-13. PubMed ID: 19616250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer.
    Shariat SF; Chade DC; Karakiewicz PI; Ashfaq R; Isbarn H; Fradet Y; Bastian PJ; Nielsen ME; Capitanio U; Jeldres C; Montorsi F; Lerner SP; Sagalowsky AI; Cote RJ; Lotan Y
    J Urol; 2010 Jan; 183(1):68-75. PubMed ID: 19913255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium.
    Shariat SF; Karakiewicz PI; Palapattu GS; Lotan Y; Rogers CG; Amiel GE; Vazina A; Gupta A; Bastian PJ; Sagalowsky AI; Schoenberg MP; Lerner SP
    J Urol; 2006 Dec; 176(6 Pt 1):2414-22; discussion 2422. PubMed ID: 17085118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival.
    Dotan ZA; Kavanagh K; Yossepowitch O; Kaag M; Olgac S; Donat M; Herr HW
    J Urol; 2007 Dec; 178(6):2308-12; discussion 2313. PubMed ID: 17936804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder.
    Karakiewicz PI; Shariat SF; Palapattu GS; Gilad AE; Lotan Y; Rogers CG; Vazina A; Gupta A; Bastian PJ; Perrotte P; Sagalowsky AI; Schoenberg M; Lerner SP
    J Urol; 2006 Oct; 176(4 Pt 1):1354-61; discussion 1361-2. PubMed ID: 16952631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers.
    Shariat SF; Youssef RF; Gupta A; Chade DC; Karakiewicz PI; Isbarn H; Jeldres C; Sagalowsky AI; Ashfaq R; Lotan Y
    J Urol; 2010 May; 183(5):1744-50. PubMed ID: 20299037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
    Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
    J Urol; 2007 Feb; 177(2):481-7; discussion 487. PubMed ID: 17222615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder.
    Margulis V; Shariat SF; Ashfaq R; Thompson M; Sagalowsky AI; Hsieh JT; Lotan Y
    J Urol; 2007 Mar; 177(3):1163-8. PubMed ID: 17296438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of cell cycle-related molecular markers in patients treated with radical cystectomy for squamous cell carcinoma of the bladder.
    Youssef RF; Shariat SF; Kapur P; Kabbani W; Ghoneim T; King E; Cockburn A; Mosbah A; Abol-Enein H; Ghoneim M; Lotan Y
    Hum Pathol; 2011 Mar; 42(3):347-55. PubMed ID: 21111452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy.
    Quek ML; Stein JP; Nichols PW; Cai J; Miranda G; Groshen S; Daneshmand S; Skinner EC; Skinner DG
    J Urol; 2005 Jul; 174(1):103-6. PubMed ID: 15947587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer.
    Isbarn H; Karakiewicz PI; Shariat SF; Capitanio U; Palapattu GS; Sagalowsky AI; Lotan Y; Schoenberg MP; Amiel GE; Lerner SP; Sonpavde G
    J Urol; 2009 Aug; 182(2):459-65; discussion 465. PubMed ID: 19524971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
    Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
    J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of p53 and pRb immunostaining in locally advanced bladder cancer treated with cystectomy.
    Jahnson S; Karlsson MG
    J Urol; 1998 Oct; 160(4):1291-6. PubMed ID: 9751338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients.
    Tilki D; Svatek RS; Novara G; Seitz M; Godoy G; Karakiewicz PI; Kassouf W; Fradet Y; Fritsche HM; Sonpavde G; Izawa JI; Ficarra V; Lerner SP; Schoenberg M; Stief CG; Dinney CP; Skinner E; Lotan Y; Sagalowsky AI; Reich O; Shariat SF
    J Urol; 2010 Sep; 184(3):888-94. PubMed ID: 20643448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.